AdvanCell Bets Big on Boston, Fueling Next Wave of Cancer-Killing Isotopes

BOSTON, MA – June 22, 2026

In a move that signals both a major commitment to the U.S. market and a significant bet on the future of cancer treatment, Australian radiopharmaceutical company AdvanCell has announced the establishment of its U.S. Global Headquarters and a sprawling 128,000-square-foot flagship manufacturing facility in Greater Boston. The new site, located at IQHQ’s Innovation Park campus in Andover, marks a pivotal moment for the clinical-stage company as it seeks to vertically integrate its operations and scale production of its promising targeted alpha therapies.

The expansion is a cornerstone of AdvanCell’s strategy to tackle one of the most complex challenges in modern oncology: manufacturing and delivering highly potent, short-lived cancer therapies. By building a substantial presence in the world’s leading biotech hub, the company is positioning itself to accelerate the development of its lead candidate, ADVC001, for metastatic prostate cancer and its wider pipeline of therapies based on the alpha-emitting isotope Lead-212 (Pb-212).

“Establishing AdvanCell’s U.S. Global Headquarters and future manufacturing facility reinforces our commitment to U.S. expansion and represents an important milestone in AdvanCell’s strategy to build a global, vertically integrated targeted alpha therapy company,” said Philina Lee, PhD, CEO of AdvanCell. “As we advance ADVC001 and our broader Lead-212 pipeline, our Andover facility will be a cornerstone of our U.S. expansion and our first internal manufacturing site in the U.S., providing the foundation to scale production to support future clinical and commercial demand.”

Boston's Biotech Ecosystem Lures Another Pioneer

AdvanCell’s decision to choose Andover is a testament to the magnetic pull of the Massachusetts life sciences corridor. The IQHQ Innovation Park campus provides not just state-of-the-art facilities but also entry into a dense network of talent, research institutions, and capital. Andover itself boasts a Platinum BioReady rating from MassBio, the highest designation available, signifying a community fully prepared with zoning, infrastructure, and a streamlined permitting process to support life science companies.

This move is more than just a real estate transaction; it’s a strategic integration into an ecosystem designed to foster rapid innovation. By co-locating corporate headquarters and manufacturing, AdvanCell can create a tight feedback loop between its executive, clinical, and production teams. The proximity to Greater Boston’s deep talent pool is expected to be a critical advantage as the company staffs up for the complex task of producing radiopharmaceuticals, a field that demands specialized expertise in both nuclear physics and pharmaceutical manufacturing.

The Alpha Advantage: A Precision Strike Against Cancer

At the heart of AdvanCell's strategy is its proprietary Lead-212 platform. The company is at the forefront of a class of treatments known as targeted alpha therapies, which are designed to function like biological smart bombs. The therapy, ADVC001, consists of a targeting molecule that seeks out Prostate-Specific Membrane Antigen (PSMA)—a protein found in abundance on the surface of prostate cancer cells—and delivers a potent, cell-killing payload of Lead-212 directly to the tumor.

Unlike more common beta-emitting radiotherapies, alpha emitters like Lead-212 release a high amount of energy over a very short distance. This creates double-strand breaks in the DNA of cancer cells, killing them with brutal efficiency while minimizing damage to surrounding healthy tissue. The 10.6-hour half-life of Lead-212 is also considered an advantage, potent enough for a therapeutic effect but short enough to reduce long-term radiation exposure for the patient.

The potential of this approach was demonstrated in the Phase 1b portion of the TheraPb clinical trial. In results presented at the European Society for Medical Oncology (ESMO) Congress, the therapy showed a favorable safety profile with no treatment-limiting toxicities. More impressively, 80% of patients with metastatic castration-resistant prostate cancer (mCRPC) treated at therapeutic doses saw their PSA levels drop by at least half. Every patient with measurable disease in that cohort experienced an objective response, including two complete responses. Based on these encouraging results, the company has advanced into a randomized Phase 2 trial to further evaluate its efficacy across different stages of metastatic prostate cancer.

Solving the Isotope Supply Chain Puzzle

For all their promise, radiopharmaceuticals face a formidable obstacle: the supply chain. The isotopes are difficult to produce, have short half-lives that make logistics a race against time, and are subject to complex nuclear and pharmaceutical regulations. The global supply of key alpha-emitting isotopes meets less than 2% of projected clinical demand, creating a significant bottleneck for clinical trials and future commercial availability.

AdvanCell's decision to build its own manufacturing facility is a direct and ambitious solution to this problem. By taking control of production—a strategy known as vertical integration—the company aims to secure a reliable and scalable supply of Lead-212. This move de-risks its clinical development and prepares it for commercial launch, a lesson learned from the struggles of other companies dependent on a fragile external supply chain. To bridge the gap while the Andover facility is being fitted out, the company is also working with a contract development and manufacturing organization (CDMO) to accelerate U.S.-based manufacturing capacity for its ongoing Phase 2 trial.

A Funded Strategy in a Competitive Market

The radiopharmaceutical market is heating up, with analysts projecting the alpha emitters market could grow from $5.8 billion in 2026 to nearly $48 billion by 2036. This has attracted major players, including Novartis, whose approved therapies Lutathera and Pluvicto have set the commercial benchmark, and Bayer, with its approved alpha-emitter Xofigo. AdvanCell is entering a competitive but rapidly expanding field.

However, the company is well-capitalized for the fight. A recently completed, oversubscribed US$112 million Series C financing round—co-led by top-tier investors including SV Health Investors and Sanofi Ventures—provides the financial muscle for the ambitious U.S. expansion. The appointment of Dr. Lee as CEO, an industry veteran with experience launching the pioneering radiopharmaceutical Xofigo, further signals that AdvanCell’s strategy is backed by both capital and deep industry expertise. By combining a promising technology, a solution to the critical supply chain problem, and a strong financial and leadership team, AdvanCell is making a compelling case that it is poised to become a major force in the future of cancer therapy.